Acid suppressive drugs and gastric cancer: A meta-analysis of observational studies

World Journal of Gastroenterology

Volumn 19, Issue 16, 2013, Pages 2560-2568

  Ahn, Jeong Soo ^a   Eom, Chun Sick ^b   Jeon, Christie Y ^c   Park, Sang Min ^a  

^a Seoul National University Hospital   (South Korea)

^b Hallym University   (South Korea)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gastric cancer; H2 receptor antagonists; Meta analysis; Proton pump inhibitors

Indexed keywords

CIMETIDINE; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE;

ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; DATA EXTRACTION; DRUG USE; HUMAN; META ANALYSIS; QUALITY CONTROL; RISK; SENSITIVITY ANALYSIS; STOMACH CANCER;

EID: 84877272906     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i16.2560     Document Type: Article

References (68)

1. Jacobson BC, Ferris TG, Shea TL, Mahlis EM, Lee TH, Wang TC. Who is using chronic acid suppression therapy and why? Am J Gastroenterol 2003; 98: 51-58 [PMID: 12526936 DOI: 10.1111/j.1572-0241.2003.07186.x]
2. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000; 118: S9-31 [PMID: 10868896 DOI: 10.1016/ S0016-5085(00)70004-7]
3. Marks RD, Richter JE, Rizzo J, Koehler RE, Spenney JG, Mills TP, Champion G. Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994; 106: 907-915 [PMID: 7848395]
4. Vigneri S, Termini R, Leandro G, Badalamenti S, Pantalena M, Savarino V, Di Mario F, Battaglia G, Mela GS, Pilotto A. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 1106-1110 [PMID: 7565948 DOI: 10.1056/NEJM199510263331703]
5. Kim JS, Chae HS, Kim HK, Cho YS, Park YW, Son HS, Han SW, Choi KY. [Spontaneous resolution of multiple fundic gland polyps after cessation of treatment with omeprazole]. Korean J Gastroenterol 2008; 51: 305-308 [PMID: 18516015]
6. Yamamoto T, Matsumoto J, Kosaihira T, Nomoto M, Kitajima S, Arima T. [A case of gastric fundic polyps during long-term treatment of reflux esophagitis with omeprazole]. Nihon Shokakibyo Gakkai Zasshi 2003; 100: 421-425 [PMID: 12722347]
7. Kazantsev GB, Schwesinger WH, Heim-Hall J. Spontaneous resolution of multiple fundic gland polyps after cessation of treatment with lansoprazole and Nissen fundoplication: a case report. Gastrointest Endosc 2002; 55: 600-602 [PMID: 11923785 DOI: 10.1067/mge.2002.122583]
8. Van Vlierberghe H, De Vos M, De Cock G, Cuvelier C, Elewaut A. Fundic gland polyps: three other case reports suggesting a possible association with acid suppressing therapy. Acta Gastroenterol Belg 1997; 60: 240-242 [PMID: 9396183]
9. Stolte M, Bethke B, Seifert E, Armbrecht U, Lütke A, Goldbrunner P, Rabast U. Observation of gastric glandular cysts in the corpus mucosa of the stomach under omeprazole treatment. Z Gastroenterol 1995; 33: 146-149 [PMID: 7754645]
10. el-Zimaity HM, Jackson FW, Graham DY. Fundic gland polyps developing during omeprazole therapy. Am J Gastroenterol 1997; 92: 1858-1860 [PMID: 9382052]
11. Hawker PC, Muscroft TJ, Keighley MR. Gastric cancer after cimetidine in patient with two negative pre-treatment biopsies. Lancet 1980; 1: 709-710 [PMID: 6103119]
12. Mullen PW. Gastric cancer in patients who have taken ci metidine. Lancet 1979; 1: 1406 [PMID: 87865 DOI: 10.1016/ S0140-6736(79)92040-3]
13. Taylor TV, Lee D, Howatson AG, Anderson J, MacLeod IB. Gastric cancer in patients who have taken cimetidine. Lancet 1979; 1: 1135-1136 [PMID: 87674]
14. Langman MJ. Antisecretory drugs and gastric cancer. Br Med J (Clin Res Ed) 1985; 290: 1850-1852 [PMID: 2860944 DOI: 10.1136/bmj.290.6485.1850]
15. Freston JW. Cimetidine: II. Adverse reactions and patterns of use. Ann Intern Med 1982; 97: 728-734 [PMID: 6753681]
16. Stockbruegger RW. Bacterial overgrowth as a consequence of reduced gastric acidity. Scand J Gastroenterol Suppl 1985; 111: 7-16 [PMID: 2861652]
17. Klinkenberg-Knol EC, Festen HP, Jansen JB, Lamers CB, Nelis F, Snel P, Lückers A, Dekkers CP, Havu N, Meuwissen SG. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121: 161-167 [PMID: 8017742]
18. Lamberts R, Creutzfeldt W, Stöckmann F, Jacubaschke U, Maas S, Brunner G. Long-term omeprazole treatment in man: effects on gastric endocrine cell populations. Digestion 1988; 39: 126-135 [PMID: 3410169 DOI: 10.1159/000199615]
19. Laine L, Ahnen D, McClain C, Solcia E, Walsh JH. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 651-668 [PMID: 10848649 DOI: 10.1046/ j.1365-2036.2000.00768.x]
20. Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 1986; 35 Suppl 1: 42-55 [PMID: 3792671 DOI: 10.1159/000199381]
21. Smith JP, Wood JG, Solomon TE. Elevated gastrin levels in patients with colon cancer or adenomatous polyps. Dig Dis Sci 1989; 34: 171-174 [PMID: 2914535 DOI: 10.1016/S00165085(98)70193-3]
22. Seitz JF, Giovannini M, Gouvernet J, Gauthier AP. Elevated serum gastrin levels in patients with colorectal neoplasia. J Clin Gastroenterol 1991; 13: 541-545 [PMID: 1744390]
23. La Vecchia C, Negri E, Franceschi S, D'Avanzo B. Histamine-2-receptor antagonists and gastric cancer: update and note on latency and covariates. Nutrition 1992; 8: 177-181 [PMID: 1356031 DOI: 10.1016/0140-6736(90)91888-H]
24. Johnson AG, Jick SS, Perera DR, Jick H. Histamine-2 receptor antagonists and gastric cancer. Epidemiology 1996; 7: 434-436 [PMID: 8793372]
25. Møller H, Nissen A, Mosbech J. Use of cimetidine and other peptic ulcer drugs in Denmark 1977-1990 with analysis of the risk of gastric cancer among cimetidine users. Gut 1992; 33: 1166-1169 [PMID: 1358764 DOI: 10.1136/gut.33.9.1166]
26. Schumacher MC, Jick SS, Jick H, Feld AD. Cimetidine use and gastric cancer. Epidemiology 1990; 1: 251-254 [PMID: 2081261]
27. Chow WH, Finkle WD, McLaughlin JK, Frankl H, Ziel HK, Fraumeni JF. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 1995; 274: 474-477 [PMID: 7629956 DOI: 10.1001/jama.1995.03530060048032]
28. Beresford J, Colin-Jones DG, Flind AC, Langman MJ, Lawson DH, Logan RF, Paterson KR, Vessey MP. Postmarketing surveillance of the safety of cimetidine: 15-year mortality report. Pharmacoepidemiol Drug Saf 1998; 7: 319-322 [PMID: 15073978]
29. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Metaanalysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012 [PMID: 10789670 DOI: 10.1001/jama.283.15.2008]
30. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in metaanalyses. Available from: URL: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm
31. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558 [PMID: 12111919 DOI: 10.1002/sim.1186]
32. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560 [PMID: 12958120 DOI: 10.1136/bmj.327.7414.557]
33. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748 [PMID: 13655060 DOI: 10.1093/ jnci/22.4.719]
34. Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet 1955; 19: 251-253 [PMID: 14388528 DOI: 10.1111/j.1469-1809.1955.tb01348.x]
35. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188 [PMID: 3802833 DOI: 10.1016/0197-2456(86)90046-2]
36. Møller H, Lindvig K, Klefter R, Mosbech J, Møller Jensen O. Cancer occurrence in a cohort of patients treated with cimetidine. Gut 1989; 30: 1558-1562 [PMID: 2599442 DOI: 10.1136/gut.30.11.1558]
37. Singh P, Indaram A, Greenberg R, Visvalingam V, Bank S. Long term omeprazole therapy for reflux esophagitis: followup in serum gastrin levels,EC cell hyperplasia and neoplasia. World J Gastroenterol 2000; 6: 789-792 [PMID: 11819697]
38. Jalving M, Koornstra JJ, Wesseling J, Boezen HM, DE Jong S, Kleibeuker JH. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther 2006; 24: 1341-1348 [PMID: 17059515 DOI: 10.1111/ j.1365-2036.2006.03127.x]
39. Eslami L, Kalantarian S, Nasseri-Moghaddam S, Majdzadeh R. Long term proton pump inhibitor (PPI) use and incidence of gastric (pre) malignant lesions. New York: John Wiley and Sons, Ltd., 2013 [DOI: 10.1002/14651858.CD007098]
40. Bateman DN, Colin-Jones D, Hartz S, Langman M, Logan RF, Mant J, Murphy M, Paterson KR, Rowsell R, Thomas S, Vessey M. Mortality study of 18 000 patients treated with omeprazole. Gut 2003; 52: 942-946 [PMID: 12801948 DOI: 10.1136/gut.52.7.942]
41. Colin-Jones DG, Langman MJ, Lawson DH, Logan RF, Paterson KR, Vessey MP. Postmarketing surveillance of the safety of cimetidine: 10 year mortality report. Gut 1992; 33: 1280-1284 [PMID: 1358768 DOI: 10.1136/gut.33.9.1280]
42. La Vecchia C, Tavani A. A review of epidemiological studies on cancer in relation to the use of anti-ulcer drugs. Eur J Cancer Prev 2002; 11: 117-123 [PMID: 11984128]
43. Solcia E, Fiocca R, Havu N, Dalväg A, Carlsson R. Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion 1992; 51 Suppl 1: 82-92 [PMID: 1397749 DOI: 10.1159/000200921]
44. Pashankar DS, Israel DM. Gastric polyps and nodules in children receiving long-term omeprazole therapy. J Pediatr Gastroenterol Nutr 2002; 35: 658-662 [PMID: 12454582 DOI: 10.1097/00005176-200211000-00013]
45. Cats A, Schenk BE, Bloemena E, Roosedaal R, Lindeman J, Biemond I, Klinkenberg-Knol EC, Meuwissen SG, Kuipers EJ. Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment. Hum Pathol 2000; 31: 684-690 [PMID: 10872661 DOI: 10.1053/hupa.2000.7637]
46. van Grieken NC, Meijer GA, Weiss MM, Bloemena E, Lindeman J, Baak JP, Meuwissen SG, Kuipers EJ. Quantitative assessment of gastric corpus atrophy in subjects using omeprazole: a randomized follow-up study. Am J Gastroenterol 2001; 96: 2882-2886 [PMID: 11693321 DOI: 10.1111/ j.1572-0241.2001.04242.x]
47. Genta RM, Rindi G, Fiocca R, Magner DJ, D'Amico D, Levine DS. Effects of 6-12 months of esomeprazole treatment on the gastric mucosa. Am J Gastroenterol 2003; 98: 1257-1265 [PMID: 12818266 DOI: 10.1111/j.1572-0241.2003.07489.x]
48. Freeman HJ. Proton pump inhibitors and an emerging epidemic of gastric fundic gland polyposis. World J Gastroenterol 2008; 14: 1318-1320 [PMID: 18322941 DOI: 10.3748/ wjg.14.1318]
49. Rindi G, Fiocca R, Morocutti A, Jacobs A, Miller N, Thjodleifsson B. Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. Eur J Gastroenterol Hepatol 2005; 17: 559-566 [PMID: 15827447 DOI: 10.1097/0004273 7-200505000-00013]
50. Lamberts R, Brunner G, Solcia E. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion 2001; 64: 205-213 [PMID: 11842276 DOI: 10.1159/ 000048863]
51. Geboes K, Dekker W, Mulder CJ, Nusteling K. Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa. Aliment Pharmacol Ther 2001; 15: 1819-1826 [PMID: 11683696 DOI: 10.1046/j.1365-2036.2001.01105.x]
52. Farrow DC, Vaughan TL, Sweeney C, Gammon MD, Chow WH, Risch HA, Stanford JL, Hansten PD, Mayne ST, Schoenberg JB, Rotterdam H, Ahsan H, West AB, Dubrow R, Fraumeni JF, Blot WJ. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control 2000; 11: 231-238 [PMID: 10782657]
53. Suleiman UL, Harrison M, Britton A, McPherson K, Bates T. H2-receptor antagonists may increase the risk of cardio oesophageal adenocarcinoma: a case-control study. Eur J Cancer Prev 2000; 9: 185-191 [PMID: 10954258 DOI: 10.1097/ 00008469-200006000-00007]
54. García Rodríguez LA, Lagergren J, Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut 2006; 55: 1538-1544 [PMID: 16785284 DOI: 10.1136/gut.2005.086579]
55. Tamim H, Duranceau A, Chen LQ, Lelorier J. Association between use of acid-suppressive drugs and risk of gastric cancer. A nested case-control study. Drug Saf 2008; 31: 675-684 [PMID: 18636786 DOI: 10.2165/00002018-200831080 -00004]
56. Duan L, Wu AH, Sullivan-Halley J, Bernstein L. Antacid drug use and risk of esophageal and gastric adenocarcinomas in Los Angeles County. Cancer Epidemiol Biomarkers Prev 2009; 18: 526-533 [PMID: 19190141 DOI: 10.1158/1055-9965. EPI-08-0764]
57. Poulsen AH, Christensen S, McLaughlin JK, Thomsen RW, Sørensen HT, Olsen JH, Friis S. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. Br J Cancer 2009; 100: 1503-1507 [PMID: 19352380 DOI: 10.1038/ sj.bjc.6605024]
58. Stockbrugger RW, Cotton PB, Eugenides N, Bartholomew BA, Hill MJ, Walters CL. Intragastric nitrites, nitrosamines, and bacterial overgrowth during cimetidine treatment. Gut 1982; 23: 1048-1054 [PMID: 7173716 DOI: 10.1136/gut. 23.12.1048]
59. Rowland JR. The toxicology of N-nitroso compounds, In Hill MJ, editors. Nitrosamines-Toxicology and Microbiology. London: Ellis Horwood, 1988: 117-141
60. Solomon TE. Trophic effects of pentagastrin on gastrointestinal tract in fed and fasted rats. Gastroenterology 1986; 91: 108-116 [PMID: 3710060]
61. Correa P. A human model of gastric carcinogenesis. Cancer Res 1988; 48: 3554-3560 [PMID: 3288329]
62. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001; 49: 347-353 [PMID: 11511555 DOI: 10.1136/gut.49.3.347]
63. Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, Lloyd D, Havu N, Frame MH, Romàn J, Walan A. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 661-669 [PMID: 10734017 DOI: 10.1016/S0016-5085(00)70135-1]
64. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HP, Liedman B, Lamers CB, Jansen JB, Dalenback J, Snel P, Nelis GF, Meuwissen SG. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018-1022 [PMID: 8598839 DOI: 10.1056/ NEJM199604183341603]
65. Eissele R, Brunner G, Simon B, Solcia E, Arnold R. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997; 112: 707-717 [PMID: 9041231 DOI: 10.1053/ gast.1997.v112.pm9041231]
66. Moayyedi P, Wason C, Peacock R, Walan A, Bardhan K, Axon AT, Dixon MF. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter 2000; 5: 206-214 [PMID: 11179985 DOI: 10.1046/j.1523-5378. 2000.00032.x]
67. Schenk BE, Kuipers EJ, Nelis GF, Bloemena E, Thijs JC, Snel P, Luckers AE, Klinkenberg-Knol EC, Festen HP, Viergever PP, Lindeman J, Meuwissen SG. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut 2000; 46: 615-621 [PMID: 10764703 DOI: 10.1136/ gut.46.5.615]
68. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-2053 [PMID: 9827707]